In potential $1.2 billion deal, Peninsula biotech sees faster path for Alzheimer's drugs
The South San Francisco biotech traces its roots back to one of the earliest disappointments in Alzheimer's drug development. Now a deal for a heart disease drug could accelerate its Alzheimer's work once again.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: Alzheimer's | American Health | Biotechnology | Cardiology | Health Management | Heart | Heart Disease